Sarah Yim said extensive research helped convince hesitant colleagues that comparative clinical trials were not needed for insulin biosimilars • Source: Alamy
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
